--- title: "ArrowHead Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 73.74 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285607988.md" datetime: "2026-05-07T20:07:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285607988.md) - [en](https://longbridge.com/en/news/285607988.md) - [zh-HK](https://longbridge.com/zh-HK/news/285607988.md) --- # ArrowHead Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 73.74 M Revenue: As of FY2026 Q2, the actual value is USD 73.74 M, beating the estimate of USD 71.71 M. EPS: As of FY2026 Q2, the actual value is USD -0.93. ### Revenue Revenue for Arrowhead Pharmaceuticals, Inc. for the three months ended March 31, 2026, was $73,737 thousand, a decrease from $542,709 thousand for the same period in 2025 . ### Operating Expenses Research and development expenses increased to $173,253 thousand in the three months ended March 31, 2026, from $133,102 thousand in the prior year period . General and administrative expenses rose to $41,744 thousand from $28,405 thousand year-over-year . Total operating expenses for the quarter were $214,997 thousand, compared to $161,507 thousand in the second quarter of 2025 . ### Operating (Loss) Income Arrowhead Pharmaceuticals, Inc. reported an operating loss of - $141,260 thousand for the three months ended March 31, 2026, a significant change from an operating income of $381,202 thousand in the comparable period of 2025 . ### Net (Loss) Income Total other income (expense) was $3,695 thousand for the current quarter, compared to - $11,586 thousand in the prior year . Loss before income tax expense and noncontrolling interest was - $137,565 thousand, versus an income of $369,616 thousand in the second quarter of 2025 . Net loss attributable to Arrowhead Pharmaceuticals, Inc. was - $132,732 thousand, or - $0.93 per diluted share, for the three months ended March 31, 2026 . This compares to a net income of $370,445 thousand, or $2.75 per diluted share, for the same period in 2025 . ### Financial Position As of March 31, 2026, total cash resources (cash, cash equivalents, restricted cash, available-for-sale securities, and short-term investments) were $1,784,091 thousand, up from $919,366 thousand as of September 30, 2025 . Total assets increased to $2,268,265 thousand from $1,385,295 thousand over the same period . Total liabilities also increased to $1,669,349 thousand from $881,879 thousand, primarily due to $681,940 thousand in convertible notes, net, which were not present as of September 30, 2025, and an increase in deferred revenue to $157,158 thousand from $2,399 thousand . Total Arrowhead Pharmaceuticals, Inc. Stockholders’ Equity was $613,977 thousand as of March 31, 2026, compared to $466,052 thousand as of September 30, 2025 . Shares outstanding were 140,571 thousand as of March 31, 2026, up from 135,702 thousand as of September 30, 2025 . ### Key Operational Metrics and Events Arrowhead Pharmaceuticals, Inc. continued to build momentum for REDEMPLO® (plozasiran) in the U.S., with over 400 total prescriptions received and approximately 180 patients having received at least one pre-filled syringe shipment . The U.S. wholesale acquisition cost (WAC) of REDEMPLO® was updated to $45,000 per patient per year . Regulatory approvals for REDEMPLO® were secured in Australia, China, and Canada, and a positive CHMP opinion was received in Europe . The company initiated a Phase 1/2a clinical trial for ARO-DIMER-PA, a dual-functional RNAi molecule targeting PCSK9 and APOC3 genes . Interim clinical data for RNAi-based obesity candidates, ARO-INHBE and ARO-ALK7, showed weight loss and improved body composition in obese patients with diabetes . Arrowhead Pharmaceuticals, Inc. entered into an exclusive worldwide license agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, receiving a $25 million upfront payment and potential milestone payments up to $975 million, plus tiered royalties . The company strengthened its balance sheet through two concurrent public offerings, raising gross proceeds of $930 million, including $700 million from convertible senior notes and $230 million from common stock or pre-funded warrants . ### Outlook The European Commission is expected to decide on REDEMPLO’s Marketing Authorization in the second quarter of 2026, and REDEMPLO is anticipated to be available later this year in Canada, marketed independently by Arrowhead Pharmaceuticals, Inc. . Management expressed confidence in driving near-term growth and long-term shareholder value by strengthening its commercial presence for REDEMPLO® and future cardiometabolic products, advancing its RNAi therapeutic pipeline, and strategic financial management . ### Related Stocks - [ARWR.US](https://longbridge.com/en/quote/ARWR.US.md) ## Related News & Research - [Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock](https://longbridge.com/en/news/286489870.md) - [Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near](https://longbridge.com/en/news/286388526.md) - [Apollo Clarifies Legal Status of Recent 8-K Disclosure](https://longbridge.com/en/news/286564452.md) - [Sanofi: Information concerning the total number of voting rights and shares - April 2026](https://longbridge.com/en/news/286946199.md) - [Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events | ARWR Stock News](https://longbridge.com/en/news/270615538.md)